27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Mesa Laboratories Inc (NASDAQ:MLAB) has agreed to acquire Agena Bioscience Inc for a cash purchase price of $300 million.
- The San Diego, California-based Agena offers genetic analysis solutions to clinical labs and development partners.
- Excluding the impact of COVID-19 related revenues, Agena is expected to add $63 million - $67 million of revenues during the first 12 months of ownership.
- Agena is also expected to deliver an additional $3 million - $5 million of COVID-19 related revenues.
- Peter Dansky, CEO of Agena, will join Mesa to lead the new Clinical Genomics Division.
- Mesa plans to complete the transaction in its Q3 ending December 31, 2021.
- Mesa expects to finance the all-cash transaction with a combination of cash on hand and proceeds from the credit facility. As of June 30, Mesa had cash and equivalents of $275.7 million.
- Price Action: MLAB stock is up 6.30% at $297.65 during the market session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!